Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: A retrospective study based on the time of HLA typing and donor availability

Blood

Volumn 115, Issue 18, 2010, Pages 3671-3677

  Sarina, Barbara ^a   Castagna, Luca ^a   Farina, Lucia ^b   Patriarca, Francesca ^c   Benedetti, Fabio ^d   Carella, Angelo M ^e   Falda, Michele ^f   Guidi, Stefano ^g   Ciceri, Fabio ^h   Bonini, Alessandro ⁱ   Ferrari, Samantha ^j   Malagola, Michele ^k   Morello, Enrico ^l   Milone, Giuseppe ^m   Bruno, Benedetto ⁿ   Mordini, Nicola ^o   Viviani, Simonetta ^b   Levis, Alessandro ^p   Giordano, Laura ^a   Santoro, Armando ^a   Corradini, Paolo ^b,q   more..

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ S MARIA NUOVA HOSPITAL   (Italy)

^j SPEDALI CIVILI   (Italy)

^k UNIVERSITY OF BRESCIA   (Italy)

^l S Maurizio Hospital   (Italy)

^m UNIVERSITY OF CATANIA   (Italy)

ⁿ UNIVERSITY OF TURIN   (Italy)

^o S CROCE E CARLE HOSPITAL   (Italy)

^p C Arrigo Children's Hospital   (Italy)

^q UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE; NAVELBINE; PREDNISONE; THIOTEPA; THYMOCYTE ANTIBODY; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; DONOR; FEMALE; FOLLOW UP; HAPLOIDY; HLA TYPING; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICIAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIBLING; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOSUPPRESSIVE TREATMENT; MULTICENTER STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77952574651     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-253856     Document Type: Article

References (29)

1. Bonfante V, Santoro A, Viviani S, et al. ABVD in the treatment of Hodgkin's disease. Semin Oncol. 1992;19[suppl 5]:S38-S45.
2. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-2071. (Pubitemid 34680969)
3. Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multi-center study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer. 2003;97(11):2748-2759. (Pubitemid 36605142)
4. Vose JM, Bierman PJ, Anderson JR, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood. 1992;80(8):2142-2148.
5. Varterasian M, Ratanatharathorn V, Uberti JP, et al. Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Leuk Lymphoma. 1995;20(1):59-65. (Pubitemid 26007430)
6. Bolwell BJ, Kalaycio M, Goormastic M, et al. Progressive disease after ABMT for Hodgkin's disease. Bone Marrow Transplant. 1997;20(9):761-765.
7. Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol. 1998;16(2):584-588. (Pubitemid 28135603)
8. Shamash J, Lee SM, Radford JA, et al. Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol. 2000;11(6):715-719.
9. Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;32(7):673-679. (Pubitemid 37258622)
10. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant. 1997;20(10):859-863. (Pubitemid 27493924)
11. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100(13):4310-4316. (Pubitemid 35429668)
12. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455-462. (Pubitemid 351171699)
13. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934-1941. (Pubitemid 40797503)
14. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12(2):172-183. (Pubitemid 43138012)
15. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007;21(11):2316-2323. (Pubitemid 350011704)
16. Castagna L, Sarina B, Todisco E, et al. Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009;15(4):432-438.
17. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reducedintensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93(2):257-264. (Pubitemid 351397714)
18. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139(1):70-80. (Pubitemid 47389932)
19. Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant. 2008;41(9):765-770. (Pubitemid 351696339)
20. Lamparelli T, van Lint MT, Gualandi F, et al. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. Bone Marrow Transplant. 2000;26(12):1305-1311. (Pubitemid 32098049)
21. Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113(19):4771-4779.
22. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
23. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57(2):267-276. (Pubitemid 11174888)
24. Labopin M, Iacobelli S. Statistical Guidelines for EBMT. http://www.ebmt.org/1whatisebmt/Op-Manual/OPMAN-StatGuidelines-oct2003.pdf. Accessed April 12, 2007.
25. Gray B. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
26. Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009;15(1):109-117.
27. Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94(2):230-238.
28. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following non-myeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279- 1287.
29. Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008;14(8):904-912. (Pubitemid 351985028)